Neutral · 60/100Aug 13, 7:17 PM EDT
Capricor's Deramiocel BLA Advances: FDA Review Continues with August PDUFA Date
CAPR
Capricor Therapeutics (CAPR) reported that its Deramiocel Biologics License Application (BLA) is under FDA review with a PDUFA target action date of August 22. Management outlined plans for a BLA amendment, signaling ongoing regulatory progress. This update is…
- ▹FDA review ongoing with PDUFA date, but no accelerated path or surrogate endpoint mentioned.
- ▹Single-asset company with limited pipeline diversity; commercial potential exists but not yet realized.
Neutral · 55/100Aug 13, 11:57 PM EDT
Celcuity Reaffirms REVTORPYK Launch Timeline and sNDA Filing for Q3 2026
CELC
Celcuity (CELC) confirmed on its Q2 2026 earnings call that it is on track to begin shipping REVTORPYK in late Q3 2026, following FDA approval for use with fulvestrant plus or minus palbociclib in HR+/HER2- advanced breast cancer. The company also targets subm…
- ▹FDA approval and planned sNDA submission indicate regulatory progress, but no accelerated path or surrogate endpoint mentioned.
- ▹Single-asset company with limited platform differentiation; commercial launch imminent but not yet generating revenue.
Neutral · 52/100Aug 14, 1:28 AM EDT
ARS Pharma Sets Sights on 2027 Cash Flow Breakeven with Cost Cuts
SPRY
ARS Pharmaceuticals (SPRY) announced plans to achieve cash flow breakeven by the end of 2027, driven by a strategic reduction in cash-based SG&A and R&D expenses to $100M-$110M in H2 2026. This cost discipline is expected to extend the company's runway and red…
- ▹Commercial product (neffy) with growing sales, but single-asset and cost-cutting focus limits upside.
- ▹No major regulatory or technology catalysts; cash flow breakeven target is positive but distant.
Neutral · 50/100Aug 14, 1:28 AM EDT
Kyntra Bio Sets Ambitious Phase III Goal for FG-3246, Targeting rPFS of 10+ Months
KYNB
Kyntra Bio (KYNB) is advancing its lead candidate FG-3246, with a Phase III start planned for Q4 2026. The company has set a median progression-free survival (rPFS) target of at least 10 months for the drug, based on promising Phase II data. Investors should w…
- ▹Phase II interim data expected Q4 2026, but no accelerated path or regulatory clarity yet.
- ▹Single-asset micro-cap with limited platform differentiation and no commercial revenue.
High Risk · 47/100Aug 13, 11:17 PM EDT
Elutia Projects NXT-41x Approval in Early 2027, Aims for Over 80% Gross Margins
ELUT
Elutia (ELUT) announced in its Q2 2026 earnings call that it expects FDA clearance for its NXT-41x product in the first half of 2027, with funding secured through that milestone. The company also targets gross margins exceeding 80% at scale, positioning it for…
- ▹NXT-41x clearance expected in 1H 2027, but no accelerated path or surrogate endpoints mentioned; regulatory timeline is long and uncertain.
- ▹Single-asset company with limited commercial traction, though funded through clearance with no equity offering, reducing near-term dilution risk.
High Risk · 45/100Aug 13, 8:47 PM EDT
Cibus Shifts Latin America Rice Launch to 2028, Sees $20M-$40M Biofragrance Opportunity
CBUS
Cibus (CBUS) has delayed its Latin America rice launch to 2028, while management highlighted a potential $20M-$40M revenue opportunity from its biofragrance products. The update came during the Q2 2026 earnings call, where new CEO Craig Wichner emphasized scal…
- ▹Rice launch delayed to 2028, indicating regulatory and commercial hurdles.
- ▹Biofragrance revenue opportunity is early-stage and uncertain, with limited near-term catalysts.